Holen Sie sich die Stockscreener-App
13.10
0.23%
0.03
Handel nachbörslich:
13.10
Schlusskurs vom Vortag:
$13.07
Offen:
$13.15
24-Stunden-Volumen:
785.58K
Relative Volume:
0.48
Marktkapitalisierung:
$1.44B
Einnahmen:
$-249.00K
Nettoeinkommen (Verlust:
$-187.60M
KGV:
-5.24
EPS:
-2.5
Netto-Cashflow:
$-201.88M
1W Leistung:
-7.75%
1M Leistung:
+6.24%
6M Leistung:
+137.32%
1J Leistung:
+197.05%
1-Tages-Spanne:
$12.92
$13.44
1-Wochen-Bereich:
$12.69
$14.76
52-Wochen-Spanne:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.10 | 1.44B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements - TipRanks
Presentation at MNDA: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial (dae63b) - marketscreener.com
Amylyx’s ALS drug AMX0114 shows positive early safety data - Investing.com India
Amylyx Pharmaceuticals announces new safety and tolerability cohort 1 data of amx0114 - marketscreener.com
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Increased by Saturn V Capital Management LP - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Lifted by Alpha Wave Global LP - MarketBeat
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
Amylyx Pharmaceuticals CMO Sells Shares to Cover Tax Obligations - TradingView
Officer Bedrosian Surrenders 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - Yahoo Finance
Key facts: Amylyx nears phase III trial for Avexitide; Bedrosian to sell shares - TradingView
Officer Bedrosian Files To Sell 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
RSI Check: Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Patterns & High Conviction Investment Ideas - moha.gov.vn
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - marketscreener.com
How Amylyx Pharmaceuticals Inc. stock trades before earningsPortfolio Update Summary & Low Risk Growth Stock Ideas - moha.gov.vn
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead - AOL.com
Kennondale Capital Management LLC Has $610,000 Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
17,551 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Acquired by ProShare Advisors LLC - MarketBeat
Amylyx Pharmaceuticals Reports Strong Q3 2025 Results - MSN
Amylyx Pharmaceuticals Inc. (AMLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How sustainable is Amylyx Pharmaceuticals Inc. stock dividend payoutWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amylyx Pharmaceuticals Inc. stock positioned for digital transformationWeekly Stock Recap & Consistent Growth Stock Picks - newser.com
Can Amylyx Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for growth ETFsOil Prices & Weekly Watchlist for Consistent Profits - newser.com
What the charts say about Amylyx Pharmaceuticals Inc. today2025 Year in Review & Stepwise Trade Signal Guides - newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceGap Up & Weekly Return Optimization Plans - newser.com
Real time social sentiment graph for Amylyx Pharmaceuticals Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):